The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

Humanity is currently facing the challenge of two devastating pandemics caused by two very
different RNA viruses: HIV-1, which has been with us for decades, and SARS-CoV-2, which …

The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA
encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly …

BACKGROUND Mosaic and consensus HIV-1 immunogens provide two distinct approaches
to elicit greater breadth of coverage against globally circulating HIV-1 and have shown …

We propose implications as to how this knowledge from natural infection can be applied in
the design and evaluation of CD8+ T-cell-based remission strategies and offer questions to …

Background An HIV-1 vaccine is long overdue. Although vaccine research focuses on the
induction of broadly neutralising antibodies, challenging infections such as HIV-1 could …

New vector and vaccine platforms: mRNA, DNA, viral vectors : Current Opinion in HIV and
AIDS New vector and vaccine platforms: mRNA, DNA, viral vectors : Current Opinion in HIV …

Infectious agents, notably viruses, can cause or increase the risk of cancer occurrences.
These agents often disrupt normal cellular functions, promote uncontrolled proliferation and …

Identifying a vaccine capable of generating durable T cell responses that target mutationally
vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a …

ABSTRACT The IL-15 superagonist N-803 has been shown to enhance the function of CD8
T cells and NK cells. We previously found that in a subset of vaccinated, ART-naive, SIV+ …